NSCLC and Theropy Clinical Trial
Official title:
A Prospective, Double-blind, Randomized Controlled Study of Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC
Based on the recommendations of the guidelines, as well as the previous animal studies and clinical studies of our team, we designed and carried out prospective, randomized controlled, double-blind clinical studies to further expand the sample size to verify the efficacy of radiofrequency ablation combined with melatonin in the treatment of stage IA NSCLC. It is hoped that this combined treatment plan can delay the recurrence of lung cancer after RFA and prolong the survival time of patients.
OBJECTIVES:
To verify the efficacy of radiofrequency ablation combined with melatonin in the treatment of
stage IA non-small cell lung cancer, and explore new directions for the prevention and
treatment of early stage non-small cell lung cancer.
OUTLINE:
This is a Prospective, double-blind, randomized controlled study. Using the same admission
criteria, it is planned to enroll 260 patients, who will be randomly assigned 1:1. The
experimental group: radiofrequency ablation combined with melatonin, and the control group:
radiofrequency ablation combined with placebo.
Intervention group: Radiofrequency ablation was performed immediately after enrollment, and
melatonin treatment was given for 6 months after 1 week after radiofrequency.
Control group: Radiofrequency ablation was performed immediately after enrollment, and a
placebo treatment program was given for 6 months after 1 week after radiofrequency.
;